{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:11:15Z","timestamp":1759342275937},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00059-017-4640-8","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T11:07:19Z","timestamp":1510052839000},"page":"336-346","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events"],"prefix":"10.1007","volume":"44","author":[{"given":"Y.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"issue":"9753","key":"4640_CR1","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Cholesterol Treatment Trialists\u2019(CTT) Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from170,000 participants in 26 randomised trials. Lancet 376(9753):1670\u20131681","journal-title":"Lancet"},{"issue":"25","key":"4640_CR2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ et\u00a0al (2012) Safety and efficacy of a\u00a0monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J\u00a0Am Coll Cardiol 59(25):2344\u20132353","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"4640_CR3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C et\u00a0al (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N\u00a0Engl J Med 367(20):1891\u20131900","journal-title":"N Engl J Med"},{"issue":"9836","key":"4640_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J et al (2012) Effect of a\u00a0monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a\u00a0phase 2 randomised controlled trial. Lancet 380(9836):29\u201336","journal-title":"Lancet"},{"issue":"19","key":"4640_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M et al (2014) 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N\u00a0Engl J Med 370(19):1809\u20131819","journal-title":"N Engl J Med"},{"issue":"23","key":"4640_CR6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M et al (2014) Anti-PCSK9 monotherapy for hypercholesterolemia:the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J\u00a0Am Coll Cardiol 63(23):2531\u20132540","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"4640_CR7","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D et al (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance:the GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab. J\u00a0Am Coll Cardiol 63(23):2541\u20132548","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"4640_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD et\u00a0al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N\u00a0Engl J Med 372(16):1500\u20131509","journal-title":"N Engl J Med"},{"issue":"16","key":"4640_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M et\u00a0al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N\u00a0Engl J Med 372(16):1489\u20131499","journal-title":"N Engl J Med"},{"key":"4640_CR10","volume-title":"Cochrane handbook for systematic reviews of interventions (version 5.1.0)","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Green S (2012) Cochrane handbook for systematic reviews of interventions (version 5.1.0). http:\/\/www.cochrane-handbook.org . Accessed 5 Jan 2012"},{"issue":"15","key":"4640_CR11","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1001\/jama.2016.3608","volume":"315","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Stroes E, Dent-Acosta RE et al (2016) Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA 315(15):1580\u20131590","journal-title":"JAMA"},{"issue":"22","key":"4640_CR12","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T et al (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316(22):2373\u20132384","journal-title":"JAMA"},{"issue":"18","key":"4640_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC et\u00a0al (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N\u00a0Engl J Med 376(18):1713\u20131722","journal-title":"N Engl J Med"},{"issue":"9858","key":"4640_CR14","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P et al (2012) Efficacy, safety, and tolerability of a\u00a0monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a\u00a0statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a\u00a0randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380(9858):2007\u20132017","journal-title":"Lancet"},{"issue":"1","key":"4640_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","volume":"117","author":"A Kiyosue","year":"2016","unstructured":"Kiyosue A, Honarpour N, Kurtz C et al (2016) A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk. Am J Cardiol 117(1):40\u201347","journal-title":"Am J Cardiol"},{"issue":"9965","key":"4640_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R et al (2015) PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 385(9965):331\u2013340","journal-title":"Lancet"},{"issue":"18","key":"4640_CR17","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ et al (2014) Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311(18):1870\u20131882","journal-title":"JAMA"},{"issue":"9","key":"4640_CR18","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","volume":"80","author":"T Teramoto","year":"2016","unstructured":"Teramoto T, Kobayashi M, Tasaki H et\u00a0al (2016) Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins \u2013 ODYSSEY JAPAN randomized controlled trial. Circ\u00a0J 80(9):1980\u20131987","journal-title":"Circ J"},{"issue":"19","key":"4640_CR19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D et\u00a0al (2015) Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart\u00a0J 36(19):1186\u20131194","journal-title":"Eur Heart J"},{"issue":"8","key":"4640_CR20","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1210\/jc.2015-1520","volume":"100","author":"H Bays","year":"2015","unstructured":"Bays H, Gaudet D, Weiss R et al (2015) Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J\u00a0Clin Endocrinol Metab 100(8):3140\u20133148","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"4640_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","volume":"28","author":"JJ Kastelein","year":"2014","unstructured":"Kastelein JJ, Robinson JG, Farnier M et al (2014) Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160\u202fmg\/dl or higher. Cardiovasc Drugs Ther 28(3):281\u2013289","journal-title":"Cardiovasc Drugs Ther"},{"issue":"43","key":"4640_CR22","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G et\u00a0al (2015) ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart\u00a0J 36(43):2996\u20133003","journal-title":"Eur Heart J"},{"issue":"6","key":"4640_CR23","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","volume":"169","author":"DJ Kereiakes","year":"2015","unstructured":"Kereiakes DJ, Robinson JG, Cannon CP et\u00a0al (2015) Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am Heart\u00a0J 169(6):906\u2013915","journal-title":"Am Heart J"},{"issue":"6","key":"4640_CR24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP et al (2015) Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a\u00a0statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J\u00a0Clin Lipidol 9(6):758\u2013769","journal-title":"J Clin Lipidol"},{"key":"4640_CR25","doi-asserted-by":"crossref","first-page":"e003421","DOI":"10.1161\/JAHA.116.003421","volume":"13;5(9","author":"E Stroes","year":"2016","unstructured":"Stroes E, Guyton JR, Lepor N et\u00a0al (2016) Efficacy and safety of alirocumab 150\u202fmg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study. J\u00a0Am Heart Assoc 13;5(9:e3421","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"4640_CR26","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Tardif JC, Amarenco P et al (2017) Lipid-reduction variability and antidrug-antibody formation with bococizumab. N\u00a0Engl J Med 376(16):1517\u20131526","journal-title":"N Engl J Med"},{"issue":"16","key":"4640_CR27","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P et al (2017) Cardiovascular efficacy and safety of bococizumab in high-risk patients. N\u00a0Engl J Med 376(16):1527\u20131539","journal-title":"N Engl J Med"},{"issue":"9943","key":"4640_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","volume":"384","author":"PM Ridker","year":"2014","unstructured":"Ridker PM (2014) LDL cholesterol: controversies and future therapeutic directions. Lancet 384(9943):607\u2013617","journal-title":"Lancet"},{"issue":"24","key":"4640_CR29","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1001\/jama.2011.860","volume":"305","author":"D Preiss","year":"2011","unstructured":"Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with Intensive-dose compared with moderate-dose statin therapy: a\u00a0meta-analysis. JAMA 305(24):2556\u20132564","journal-title":"JAMA"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-017-4640-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-017-4640-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T16:55:52Z","timestamp":1659804952000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-017-4640-8"}},"subtitle":["A\u00a0meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4640"],"URL":"https:\/\/doi.org\/10.1007\/s00059-017-4640-8","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]},"assertion":[{"value":"21 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.\u00a0Zhu, X.\u00a0Shen, Q.\u00a0Jiang, Z.\u00a0Wang, Z.\u00a0Wang, X Dong, J.\u00a0Li, Q.\u00a0Han, J.\u00a0Zhao, B.\u00a0Wang, and L.\u00a0Liu declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. The ethical guidelines of the studies analyzed in this article are provided within the respective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}